Research programme: anti-Flightless I antibody - AbRegen

Drug Profile

Research programme: anti-Flightless I antibody - AbRegen

Alternative Names: Anti-Flightless I antibody - AbRegen

Latest Information Update: 22 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of South Australia
  • Developer AbRegen
  • Class Antibodies; Skin disorder therapies
  • Mechanism of Action FLII protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Epidermolysis bullosa

Most Recent Events

  • 22 Jun 2017 AbRegen plans a phase II trial for Epidermolysis in Australia (AbRegen pipeline, June 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top